1. Investor Presentation
NASDAQ: FHCO
Investor Presentation
Q1 2016

2. Yellow shading shows distribution of FC2
Female Health Company
Markets FC2 Female Condom Worldwide 519 Million Units Sold to Date Saves Lives and Reduces Healthcare Costs Improves Women’s Health
Yellow shading shows distribution of FC2 2

3. FC2 Female Condom FC2 is the only product currently available:
Approved by the FDA and cleared by the World Health Organization (WHO)
Under a women’s control
Which provides dual protection against:
Unintended pregnancy
Sexually transmitted infections (STIs), including HIV/AIDS and Zika Virus

4. At a Glance NASDAQ FHCO Core product FC2 Female Condom
Gross margin ~66%
Operating margin ~29%
Total current assets $24 million
no L/T debt at 12/31/15
Profitable Starting 2006
Debt Free $10M Unused Credit Facility

5. FC2 Market Women’s Health Issues
HIV/AIDS
Leading cause of death globally for women age 15-44
80% of female cases contracted via heterosexual transmission
Male and female condoms are the only prevention products available
No near-term broad-use alternative prevention products on the horizon
STIs
Explosive incidence numbers around the world
In U.S., Center for Disease Control (CDC) sees 20 million new cases annually of the 3 STIs tracked; half of cases occur within the age group and accounts for almost $16 billion in healthcare costs
In Sub-Saharan Africa, women
represent >58% of adults
with HIV/AIDS infections (1)
Worldwide, women living with
HIV/AIDS is 50% of the global total (1)
(1) Source: World Health Organization

6. Developments
Recent
Zika Virus(1) WHO Declares Global Emergency: Emerging Women’s Health Issue
Babies
Devastating birth defects
Microcephaly – head and brain abnormalities
Transmission
Via mosquito bite
Sexually transmitted
Adults
Possible link to Guillain-Barré Syndrome
Neurological disorder that can cause muscle weakness, paralysis, and death
Impact
33 countries and territories impacted
6 more showing indications of such transmission and 7 experiencing a parallel rise of microcephaly and Guillain-Barré
As many as 4 million people could be impacted by 2016 year end
Prevention
Women who become infected while or before becoming pregnant may give birth to babies with significant birth defects including head and brain abnormalities.
Female and male condoms are the only products that can prevent pregnancy and infection through sexually transmitted infections.
(1) Source: World Health Organization and CDC

7. UNAIDS Calls For 20 Billion Condoms A Year By 2020(1)
Developments
Recent
UNAIDS Calls For 20 Billion Condoms A Year By 2020(1)
Every day more than 1 million people acquire a sexually transmitted infection.
80 million unintended pregnancies occur every year.
“UNAIDS is calling for increased investments by donors and governments for promotion and distribution of male and female condoms in order to ensure everyone has access to condoms to protect themselves and their partners from HIV, STIs, and unintended pregnancies – investing in condoms saves lives” UNAIDS Deputy Executive Director Luiz Loures.
(1) Source: United Nations Joint Programme on HIV/AIDS

8. Global Condom Public Health
The Condoms Markets
Consumer Global Public Sector
Global Market
$4 – 6 Billion
Units ~10 – 12 Billion
Family Planning
HIV/AIDS
Global Condom Public Health
$ 400 – 500 Million
Units ~10 Billion

9. FC2 Female Condom vs. Male Condom
FC2 is an alternative to the male condom
Found to be preferred by
women and partners in many countries
Material, nitrile polymer, is stronger than latex, reducing the probability of tearing, and is non-allergenic
Allows the woman to take control of protection
Transfers heat, warming to body temperature for natural feeling sex
Non-interruptive, can be inserted in advance of sexual activity
Reduces health costs by increasing HIV/AIDS prevention and decreasing STI’s*
* Every $1 spent on Female Condoms represents $20 in healthcare savings per the Johns Hopkins
Washington D.C. Study published in AIDS and Behavior, 2012.

10. FC2 Market Advocacy
One of few markets where independent groups advocate use of company’s product
Well organized and funded independent women’s groups
Advocate for gender equality
Through increased funding for/availability of female condoms worldwide
Examples
Center for Health and Gender Equity (CHANGE) – Washington, D.C.
Universal Access to Female Condoms (UAFC) – Netherlands
UAFC Sponsors
Global Female Condom Conference 2015 – Durban, RSA, Dec 1-3, 2015
Worldwide attendees
Meeting mission: “Make female condoms available/affordable for all”
Positive long term market impact

11. Market Changes and Potential Expansion Opportunities
US Market Changes
Female condoms (FC2) reimbursable under Obamacare
Growing need for non-hormonal birth control
Role of social marketing to young women
Increasing online purchases of condoms
US Potential Opportunities
Direct-to-consumer marketing
Women seeking non-hormonal birth control
Female condoms less disruptive, more pleasurable
Selling FC2 to institutions where non-hormonal birth control products are important, i.e. for patients with breast cancer
Selling to health care organizations/physicians to access reimbursement from Obamacare
Online sales via Walmart/ShopFemaleHealth.com/Amazon/Walgreens/CVS

12. Market Changes and Potential Expansion Opportunities
Worldwide Market Changes
Zika virus can be sexually transmitted
Can impact pregnant women and their babies with devastating birth defects
Microcephaly (babies)
Guillain-Barré Syndrome (adults)
Potential to become global epidemic (up to 4 million impacted by year end)
Detected in 33 countries and territories
UNAIDS Call for 20 Billion Male and Female Condoms by 2020(1)
UNAIDS calls for increased investments by donors and governments
Objective is to ensure everyone has access to condoms
“Investing in condoms saves lives,” said UNAIDS Deputy Executive Director Luiz Loures
(1) Source: UNAIDS – February 12, 2016

13. Online Sales ShopFemaleHealth.com Amazon.com Walgreens.com CVS.com
Walmart.com
Kmart.com
MyQuestStore.com
Drugstore.com 13

14. Product Development Consumer: What’s Next
Coming Soon:
Updated Branding
Updated Packaging
New Product Colors – submitted for appropriate quality approvals
Marketing campaign to target users
To include social media, PR, targeted advertising 14

15. Competitive Barriers To Entry
Patents principally on use of nitrile and nitrile/design elements:
39 patents in 52 countries; expiring in 2023 and 2024
FDA approval/WHO clearance
FC2 proprietary material formulation
Worldwide product specific training and education
Country registration process 15

16. FC2 Competition Cupid PATH – Women’s Condom Marketed Globally
Marketed Outside U.S.
Not Marketed
Only one other female condom approved by WHO – Cupid – not approved by FDA

17. Competition FC2 Cupid PATH – Women’s Condom Nitrile Polymer
Natural rubber latex
Polyurethane
2 retention rings:
External ring covers the lips of the vagina
Internal ring lies against the cervix and anchors the device
Octagonal outer ring. Sponge to anchor the device internally.
Large external ring:
-Tabs on the exterior of the device that reportedly adhere to the vaginal wall
- Inserter made from a water soluble polymer that melts in the body and may help keep the product in place
Non-allergenic
Allergenic
Pre-lubricated
Not Pre-lubricated
-Must be lubricated at time of use
-Only internal side of product may be lubricated. External lubrication may prevent tabs from working
May use water and oil based lubricants
May only use water based lubricants
May be inserted in advance
FHC capacity 100MM, with ability to double
Website indicates approx 10MM capacity

18. Competitive Impact on FHC
First competitive product cleared by WHO – June 2012
After 3 years of competition achieved no significant market share
FHC remains market leader as demonstrated by 2015 results

19. FHC Strategy Focus: return on investment/impact on shareholder value
Capitalize on: long-term female condom public sector growth; FHC’s position as market leader
FC2 product development/marketing
Pursue female condom market expansion opportunities – direct-to-consumer/online purchasing
Diversify product line based on ROI/impact on shareholder value

20. Key Project Status Direct to Consumer Promotion
6 month study completed this quarter
Diversification of Product Line
Specific opportunities identified and under evaluation

21. Why FC2 Demand Will Continue To Grow
Zika virus outbreak
Potential to become global epidemic
UNAIDS calls for 20 billion male and female condoms by 2020(1)
Continued Global Focus on HIV
Feminization of AIDS – leading cause of death women age 15-44
35 million persons living with AIDS, 2.3 million newly infected in 2012
Exploding incidence of STIs around the world
20M new cases every year in the US alone, half occurring in young people aged 15-24
Tapping into Direct-to-Consumer Market, Non-hormonal birth control alternative, Online Sales
Many US women report dissatisfaction with the side effects of hormonal birth control
Advocacy by independent women’s groups
Create gender equality and increase funding for global availability of female condoms
(1) Source: UNAIDS – February 12, 2016

22. Talented Management Team
O.B. Parrish – Chairman and Chief Executive Officer
Effective July 13, 2015
Oversees Sales and Marketing
A FHCO founder
Previous Experience
Pfizer – Executive V.P. of International Division
G.D. Searle – President of Global Pharmaceuticals
Michele Greco – Executive Vice President and Chief Financial Officer
Effective January 1, 2013
Ernst & Young LLP Audit Partner
Martin Tayler – Executive Vice President of Global Operations
Effective September 15, 2014
Previous Experience
SSL International PLC (under Durex and Dr Scholl’s brands),Reckitt Benckiser Group plc

23. State-of-the-Art Manufacturing
100 million unit capacity, with ability to add
up to an additional 100 million units.

24. Low Risk, Unique Business Model
Modest inventory level, production primarily against orders
Low foreign currency exchange risk, FHCO & Subs Report in $USD
Minimal credit risk, less than 1% bad debt in past five years
$10M unused credit facility
NOL carryforward:
UK: ~$62 M – No expiration date
US: ~$13 M – Expiring in years 2020 to 2027
State: ~$13 M – Expiring in years 2020 to 2027

25. Tax Loss Carryforward FHC: No longer records P&L NOL benefit
Records tax charge
Continues to benefit from NOL cash impact
Example:
Q1 FY2016
Tax Charge - $ ,453
Taxes Paid - $ ,856
Cash Saved - $ ,597

26. FY 2016 – 2015 Results Profitable starting in 2006 No debt
YTD 2016
(millions, except EPS)
YTD 2015
Units
15.4
12.2
Revenue
$8.2
$6.7
Gross Margin
$5.4
$3.8
Operating Income
$2.4
$1.5
Tax Expense
$0.8
$0.7
Net Income
EPS - Diluted
$0.05
$0.03
Tax-cash payments
$0.07
$0.06
Adjusted EBITDA
$2.6
$1.8
EPS – Diluted, as adjusted
$0.09
Profitable starting in 2006
No debt
Brazil tender for up to 50 million units: 37 million units shipped
Strategy to accelerate growth in current markets and expand into new markets
NOL’s utilized to reduce cash payments for income taxes

27. Unit Sales CAGR 16 % 61.0 54.8 42.5 19.6 15.4 FC1 FC1 & FC2 FC2
100% sales of lower price, higher margin, next generation FC2
CAGR
16 %
61.0
54.8
42.5
19.6
15.4
FC1
FC1 & FC2
FC2

28. Net Revenues $32.6 $31.5 $24.5 $14.8 $8.2 FC1 FC1 & FC2 FC2
100% sales of lower price,
higher margin,
next generation FC2
$32.6
$31.5
$24.5
$14.8
$8.2
FC1
FC1 & FC2
FC2

29. Gross Margin 65.6 58.2 53.6 37.0 FC1 FC1 & FC2 FC2
100% sales of lower price,
higher margin,
next generation FC2
58.2
65.6
53.6
37.0
FC1
FC1 & FC2
FC2

30. FHC Summary Stable, profitable company
New strategy focused on driving Company growth
Potential 10 billion unit condom market virtually untapped = opportunity for growth
Experienced leadership with track record of success 30